Shots:
- AstraZeneca to present Tagrisso’s data from P-III (LAURA & FLAURA2) & P-II (SAVANNAH & ORCHARD) trials at ELCC 2025 for EGFRm NSCLC pts who failed or received 1L therapy; data to support global filings
- In LAURA, Tagrisso showed favorable OS trend (mOS: 58.8 vs 54.1mos.; maturity: 31%) despite 78% of PBO pts receiving it post-progression while in SAVANNAH, Tagrisso + Orpathys achieved 56% ORR, 7.1mos. mDoR, & 7.4mos. mPFS
- In ORCHARD, Tagrisso + Datroway (6mg/kg) had 36% ORR vs 43% with 4mg/kg but showed better PFS (11.7 vs 9.5mos.) & durability (64% vs 15% at 9mos.); Datroway ± Tagrisso is also in P-III (TROPION-Lung14 & 15) trial for EGFRm NSCLC. In FLAURA2, mPFS exceeded 2yrs.; OS remain immature
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Collaborates with Syneron Bio to Develop Macrocyclic Peptides for Chronic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
